Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:1904-1909
Published online before print August 4, 2005, doi: 10.1161/01.STR.0000178543.19433.20
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/9/1904    most recent
01.STR.0000178543.19433.20v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ainsworth, C. D.
Right arrow Articles by Spence, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ainsworth, C. D.
Right arrow Articles by Spence, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*Ultrasound
Related Collections
Right arrow Other diagnostic testing
Right arrow Imaging
Right arrow Doppler ultrasound, Transcranial Doppler etc.

(Stroke. 2005;36:1904.)
© 2005 American Heart Association, Inc.


Original Contributions

3D Ultrasound Measurement of Change in Carotid Plaque Volume

A Tool for Rapid Evaluation of New Therapies

Craig D. Ainsworth, MD; Christopher C. Blake, MSc; Arturo Tamayo, MD; Vadim Beletsky, MD; Aaron Fenster, PhD J. David Spence, MD

From the Stroke Prevention and Atherosclerosis Research Centre (C.D.A., A.T., V.B., J.D.S.) and Imaging Research Laboratories (C.C.B., V.B., A.F., J.D.S.), Robarts Research Institute, London, Canada.

Reprint requests to Professor David Spence, Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, 1400 Western Rd, London, ON, Canada N6G 2V2. E-mail dspence{at}robarts.ca

Background and Purpose— New therapies are being developed that are antiatherosclerotic but that lack intermediate end points, such as changes in plasma lipids, which can be measured to test efficacy. To study such treatments, it will be necessary to directly measure changes in atherosclerosis. The study was designed to determine sample sizes needed to detect effects of treatment using 3D ultrasound (US) measurement of carotid plaque.

Methods— In 38 patients with carotid stenosis >60%, age±SD 69.42±7.87 years, 15 female, randomly assigned in a double-blind fashion to 80 mg atorvastatin daily (n=17) versus placebo (n=21), we measured 3D plaque volume at baseline and after 3 months by disc segmentation of voxels representing carotid artery plaque, after 3D reconstruction of parallel transverse duplex US scans into volumetric 3D data sets.

Results— There were no significant differences in baseline risk factors. The rate of progression was 16.81±74.10 mm3 in patients taking placebo versus regression of –90.25±85.12 mm3 in patients taking atorvastatin (P<0.0001)

Conclusions— 3D plaque volume measurement can show large effects of therapy on atherosclerosis in 3 months in sample sizes of {approx}20 patients per group. Sample sizes of 22 per group would be sufficient to show an effect size of 25% that of atorvastatin in 6 months. This technology promises to be very useful in evaluation of new therapies.


Key Words: atherosclerosis • carotid artery plaque • ultrasonography




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
J. R. Crouse III
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699.
[Abstract] [Full Text] [PDF]